# Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products

> **NCT00515944** · PHASE1 · COMPLETED · sponsor: **Merz Pharmaceuticals GmbH** · enrollment: 30 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Botulinum neurotoxin type A, free of complexing proteins

## Key facts

- **NCT ID:** NCT00515944
- **Lead sponsor:** Merz Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-02
- **Final completion:** 2008-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2009-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515944, "Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00515944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*